Companies › Leadiant Biosciences
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ManNAc (N-acetyl-D-mannosamine monohydrate) Precursor for N-acetylneuraminic acid (Neu5Ac) biosynthesis; restores glycan sialylation i | GNE | Phase 2 | GNE Myopathy; Focal Segmental Glomerulosclerosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04231266 | ManNAc (N-acetyl-D-mannosamine monohydrate) | Phase 2 | GNE Myopathy | Neurology | Jun 2025 |
| NCT06664814 | ManNAc (N-acetyl-D-mannosamine monohydrate) | Phase 2 | Focal Segmental Glomerulosclerosis | Genitourinary | Nov 2030 |
–
Woolsey Pharmaceuticals Actinogen Medical Abrexa Pharmaceuticals Neuron23 Bial R&D Investments
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.